Fulcrum Therapeutics is developing small molecules for rare diseases, including those related to sickle cell disease, and has a director involved in the VCU Adult Sickle Cell Program.
1 report, 1 independent
Updated Jul 29
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Fulcrum Therapeutics is developing small molecules for rare diseases, including those related to sickle cell disease, and has a director involved in the VCU Adult Sickle Cell Program.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Fulcrum Therapeutics (United States)
company in Cambridge, United States
Coverage
Newest first; wire copies grouped- GlobeNewswireFulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therap